In:
Cancer Medicine, Wiley, Vol. 5, No. 12 ( 2016-12), p. 3437-3444
Abstract:
Advanced stage leiomyosarcoma ( LMS ) is incurable with current systemic antitumor therapies. Therefore, there is clinical interest in exploring novel therapeutic regimens to treat LMS . We reviewed the medical records of 75 consecutive patients with histologically confirmed metastatic LMS , who had been referred to the Clinical Center for Targeted Therapy at MD Anderson Cancer Center. To lay the foundation for potential phase I trials for the treatment of advanced LMS , we analyzed tumor response and survival outcome data. The frequent hotspot gene aberrations that we observed were the TP 53 mutation (65%) and RB 1 loss/mutation (45%) detected by Sequenom or next‐generation sequencing. Among patients treated with gene aberration‐related phase I trial therapy, the median progression‐free survival was 5.8 months and the median overall survival was 15.9 months, significantly better than in patients without therapy (1.9 months, P = 0.001; and 8.7 months, P = 0.013, respectively). Independent risk factors that predicted shorter overall survival included hemoglobin 〈 10 g/dL, body mass index 〈 30 kg/m 2 , serum albumin 〈 3.5 g/ dL , and neutrophil above upper limit of normal. The median survivals were 19.9, 7.6, and 0.9 months for patients with 0, 1 or 2, and ≥3 of the above risk factors, respectively ( P 〈 0.001). A prognostic scoring system that included four independent risk factors might predict survival in patients with metastatic LMS who were treated in a phase I trial. Gene aberration‐related therapies led to significantly better clinical benefits, supporting that further exploration with novel mechanism‐driven therapeutic regimens is warranted.
Type of Medium:
Online Resource
ISSN:
2045-7634
,
2045-7634
DOI:
10.1002/cam4.2016.5.issue-12
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
2659751-2